Bardin Hill Management Partners’s Aimmune Therapeutics AIMT Stock Holding History

Bardin Hill Management Partners’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-305,457	Closed	-$10.5M	–	55
2020 Q3	$10.5M	Buy	+305,457	New	+$6.51M	2.79%	14

Bardin Hill Management Partners's AIMT Position: Q4 2020 in Review

Bardin Hill Management Partners sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 305,457 shares — an estimated $10.5M sold.

Bardin Hill Management Partners first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $10.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Bardin Hill Management Partners reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Bardin Hill Management Partners sold 305,457 Aimmune Therapeutics shares in Q4 2020, an estimated $10.5M.
Bardin Hill Management Partners first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Bardin Hill Management Partners's Aimmune Therapeutics position peaked at $10.5M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Bardin Hill Management Partners's 13F filing for Q4 2020, filed 16 Feb 2021.